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OPEN
REVIEW
Lifestyle guidelines for managing adverse effects on bone
health and body composition in men treated with androgen
deprivation therapy for prostate cancer: an update
PJ Owen1, RM Daly1, PM Livingston2 and SF Fraser1
BACKGROUND:Men treated with androgen deprivation therapy (ADT) for prostate cancer are prone to multiple treatment-induced
adverse effects, particularly with regard to a deterioration in bone health and altered body composition including decreased lean
tissue mass and increased fat mass. These alterations may partially explain the marked increased risk in osteoporosis, falls, fracture
and cardiometabolic risk that has been observed in this population.
METHODS: A review was conducted that assessed standard clinical guidelines for the management of ADT-induced adverse effects
on bone health and body composition in men with prostate cancer.
RESULTS: Currently, standard clinical guidelines exist for the management of various bone and metabolic ADT-induced adverse
effects in men with prostate cancer. However, an evaluation of the effectiveness of these guidelines into routine practice revealed
that men continued to experience increased central adiposity, and, unless pharmacotherapy was instituted, accelerated bone loss
and worsening glycaemia occurred.
CONCLUSIONS: This review discusses the current guidelines and some of the limitations, and proposes new recommendations
based on emerging evidence regarding the efﬁcacy of lifestyle interventions, particularly with regard to exercise and nutritional
factors, to manage ADT-related adverse effects on bone health and body composition in men with prostate cancer.
Prostate Cancer and Prostatic Diseases (2017) 20, 137–145; doi:10.1038/pcan.2016.69; published online 24 January 2017
INTRODUCTION
Prostate cancer (PCa) is the most commonly diagnosed male
cancer in developed countries.1 Treatment for PCa includes
surgery, radiotherapy, androgen deprivation therapy (ADT) and
chemotherapy, which is inﬂuenced by the stage and aggressive-
ness of the cancer.2,3 Although usually reserved for non-localised
or more aggressive PCa, ADT is a standard systemic treatment that
aims to reduce the activity and/or concentration of androgens,
such as testosterone, to castration levels to prevent PCa growth
and spread.4 Various modalities of ADT, including those adminis-
tered neoadjuvant or adjuvant with other treatments are
associated with improved survival in appropriately selected men
with advanced PCa.5–9 In contrast, evidence that ADT prolongs
survival in men with localised PCa remains limited and, therefore,
debated.10–12 Despite this, ADT is commonly prescribed for both
metastatic4 and non-metastatic PCa.13
Although ADT has been shown to improve survival outcomes,
treatment-induced hypogonadism has been associated with
multiple interconnected adverse effects such as decreased bone
mineral density (BMD) and a loss in the structure and strength of
bone,14–25 a loss in lean tissue mass and muscle cross-sectional
area,17,18,20,26–31 an increase in fat mass and intermuscular adipose
tissue17,18,20,26–28,31,32 and an increased risk of falls33 and
subsequent fractures in this clinical population group.34–36 Other
commonly observed adverse effects of ADT include negatively
altered blood lipid proﬁles, decreased insulin sensitivity, increased
arterial stiffness, increased fatigue, increased depressive
symptoms and sexual dysfunction.37–39 Collectively, these altera-
tions may lead to increased cardiometabolic risk and decreased
health-related quality of life in men treated with ADT.40,41 The aim
of this paper was to review the current guidelines available for
management of various bone and metabolic ADT-induced adverse
effects in men with PCa. A secondary aim was to propose new
recommendations based on emerging evidence regarding the
efﬁcacy of lifestyle interventions, particularly with regard to
exercise and nutritional factors, to manage ADT-related alterations
to bone health and body composition in men with PCa.
MATERIALS AND METHODS
An electronic search of the National Institute of Health MEDLINE
database was performed to identify all peer-reviewed articles
published in English between January 2000 and June 2016. The
following search terms were used: (‘androgen deprivation therapy’
or ‘hormone therapy’) and (‘guidelines’ or ‘strategies’ or ‘practice’)
and (‘bone’ or ‘muscle’ or ‘fat’ or ‘body composition’). Overall, 276
articles were found, of which the titles and abstracts were
evaluated by two authors (PJO and SFF). Additional articles were
located via manual searches of relevant reference lists. Five articles
discussing recently proposed and relevant lifestyle guidelines
for the management of ADT-induced adverse effects on bone
health and body composition were determined as the basis for
this review.
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Changes to bone health and body composition associated with
androgen deprivation therapy
Bone mineral density, structure and strength. It is well established
that there is a progressive age-related loss in areal BMD (aBMD) in
healthy men, as commonly measured via dual-energy X-ray
absorptiometry (DXA), which equates to ~ 0.5–1.0% per year at
various skeletal sites including the femoral neck, total hip and
lumbar spine42,43 (Figure 1). In contrast, it has been reported that
men treated with continuous pharmacological ADT experience
aBMD annual losses of 0.6–3.9% at the femoral neck14–16,21–23,44
and 2.3–4.8% at the lumbar spine,15,18,21–23,25,44 particularly during
the initial 6 months of treatment (Table 1 and Figure 1).
Accelerated aBMD loss has also been observed at the
hip,17–20,22–25,44,45 radius18,22,24,44 and whole body,17,18 indicating
that ADT has a systemic effect on bone (Table 1). The ﬁndings
from a 12-month prospective study using high-resolution
peripheral quantitative computed tomography, which quantiﬁes
changes in appendicular cortical and trabecular volumetric BMD
and microarchitecture, reported that men treated with ADT (mean
age; 71 years) experienced losses in distal radius and tibia cortical
volumetric BMD of up to 11.3% and 6.0% per year, respectively44
(Figure 1). Losses in trabecular volumetric BMD of 3.5% and 1.5%
were also observed at the distal radius and tibia, respectively44
(Figure 1). In addition, cortical area at the distal radius and tibia
decreased by 5.1–5.2% within the ﬁrst 6 months which increased
to 11.5–12.5% after 12 months44 (Figure 1). This study indicates
that both the density and structure of bone, which are both
important determinants of whole-bone strength, are compro-
mised in men treated with ADT. Furthermore, the study indicates
that DXA-based measures of aBMD may underestimate the
magnitude of bone loss associated with ADT.
There is also evidence that the rate of bone loss in men with
PCa may be dependent on the modality of treatment. For
instance, orchiectomy appears to lead to greater aBMD loss when
compared with pharmacological ADT,14,16 whereas anti-androgen
monotherapy has been associated with reduced bone loss
compared with gonadotropin-releasing hormone agonists.25
Duration of ADT may also inﬂuence the rate of bone loss, with
the greatest losses occurring within the ﬁrst 6 months of
treatment.18 From a clinical perspective, accelerated loss of bone
density and structure during ADT is important because it likely
contributes to the marked increase in fracture risk (34–65%) in this
susceptible population group, which has been associated with
twice the rate of mortality when compared with men on ADT who
did not sustain a fracture.34,46 Importantly, there is also evidence
of a signiﬁcant dose–response relationship between the number
of ADT doses received during the 12 months post diagnosis and
the subsequent risk of fracture.35,47 In addition to ADT, residual
effects of radiotherapy have been postulated to inﬂuence
androgen concentration,48 which supports the ﬁndings from a
meta-analysis indicating that men who had not received ADT for
PCa had lower aBMD than healthy older males, but not as low as
men treated with ADT.49
Lean tissue mass. In healthy adult men, age-related losses in lean
tissue mass range from 1.0-2.0% per year after the age of 40–45
years, with a more accelerated loss after the ﬁfth decade of
life.50,51 However, lean tissue mass losses of 2.0–3.6% have been
reported after a year of ADT18,20,28,44 (Table 2). In addition, ﬁndings
from a study of 25 men (mean age; 68 years) who had
commenced ADT reported that lean tissue mass decreased by
1.4% in the ﬁrst 12 weeks of treatment.29 Although the mediating
factors contributing to muscle loss with ADT are multifaceted,
duration of treatment and patient age appears to be important.
For instance, men treated with ADT demonstrated the greatest
losses in lean tissue mass (2.6–3.2%) during the initial 6–9 months
of treatment.18,44,52 Furthermore, men on ADT aged 470 years
have been shown to lose three times the amount of lean tissue
mass when compared with men aged o70 years.52 These
changes to lean tissue mass may adversely affect functional
performance as observed during a follow-up of 50 men (median
age; 78 years) treated with ADT in which 24% of the men
demonstrated impairment during activities of daily living.33
Moreover, 22% of these men reported a recent fall,33 which may
further increase the risk of fracture. Notably, after cessation of ADT
and recovery of eugonadal testosterone level, lean tissue mass
losses were not reversed over a 2-year follow-up in a cohort of 49
men (mean age; 73 years).32 This suggests that the associated
complications of ADT may be prolonged after cessation of
treatment.
Fat mass. During the ageing process, fat mass and percentage
body fat commonly increases in men until the seventh decade,
after which it typically remains stable or decreases slightly
throughout the remainder of life.53 Conversely, men on ADT have
been shown to experience a continuous increase in fat mass
beyond this age-associated plateau (Table 2) with an average
annual gain exceeding 11%.54 Furthermore, following a 2-year
period after cessation of ADT, negative alterations to fat mass
remained.32 To date, limited studies have quantiﬁed if there are
region-speciﬁc gains in fat mass during ADT,27,55,56 but of the
limited research available, ADT has been associated with an 11–
13% increase in subcutaneous abdominal fat mass27,55 and either
an increase (22%)55 or no change27 in visceral abdominal fat mass
after 48–52 weeks. In addition, ﬁndings from a study of 39 men
(median age; 73 years) commencing ADT reported increased fat
inﬁltration of lower limb muscles (anterior compartment of thigh),
as assessed via computed tomography, after 14.6–20 weeks of
treatment.56 Clinically, there are multiple adverse consequences
associated with these ADT-related gains in total and regional fat
mass and intramuscular fat. For instance, potential increases in
subcutaneous and visceral fat may contribute to the marked
increase in cardiometabolic disorders in men treated with
ADT.28,40,57 In addition, increased fat inﬁltration within muscle
has been shown to impair muscular function in non-ADT-treated
older adults.58 As obesity is associated with an increase in
inﬂammatory cytokines (or adipokines),59 and chronic systemic
inﬂammation has been shown to contribute to age-related muscle
wasting,60 it is possible that ADT-induced gains in fat mass may
exacerbate losses in muscle in men with PCa.
Figure 1. Effects of ADT on bone mass, structure and strength.
aBMD, areal bone mineral density; ADT, androgen deprivation
therapy; vBMD, volumetric bone mineral density.
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Potential treatment options for addressing bone health and body
composition changes associated with androgen deprivation
therapy
Current guidelines for managing ADT-induced adverse effects on
bone, muscle and fat generally apply a similar approach, that is,
monitoring known risk factors, pharmacotherapy and/or lifestyle
interventions, but these management guidelines appear to vary
by country, organisation and expert opinion.37,40,61–63 Although
these guidelines are often based on numerous evidence-based
studies, it remains uncertain as to whether these guidelines are
routinely implemented and followed over time and if they are
effective in ameliorating or attenuating many of the adverse
effects of ADT. To date, only one set of guidelines,40 focusing on
bone and metabolic outcomes of ADT, has been implemented and
evaluated.64 In a 2-year prospective study, 236 men with PCa
commencing ADT attended a baseline clinic visit and received diet
and lifestyle advice, with overweight and obese men offered
referral to a dietician.64 If required, men also received treatment
for hypertension, hypercholesterolaemia and osteoporosis as per
standard management guidelines.40 Men attending this clinic
were assessed at 3–6 monthly intervals.64 A summary of the
assessment and management strategies used in this study is
shown in Table 3. At the initial assessment, 87% of the men were
overweight/obese, 61% had hypertension, 56% had hypercholes-
terolaemia, 27% had prior cardiovascular disease, 11% had
osteoporosis and 40% had osteopenia.64 For the prospective
study, 153 men had data available after 2 years of continuous ADT
use.64 The main ﬁndings from this study were a mean loss of 3.4%
and 2.5% in lumbar spine (L1-4) and hip aBMD, respectively, over 2
years, unless the men were treated with antiresorptive therapy
(n= 14), in which case aBMD was maintained at both the sites.64
No measures of muscle or fat mass or functional performance
were assessed in this study, however, an increase in waist
circumference of 2.7 cm was indicative of an increase in
abdominal fat mass.64 In contrast, reductions were observed in
blood pressure, total cholesterol and low-density lipoprotein
cholesterol with treatment.64 Although it is important to acknowl-
edge that this was an observational study, which precludes
inferences about causality, these ﬁndings provide some evidence
that adhering to the current management guidelines for men with
PCa treated with ADT may not mitigate some of the metabolic and
bone adverse effects associated with this treatment.
Table 1. Non-randomised controlled trials examining the effects of continual ADT in men with prostate cancer on aBMD
Authors N Average age (years) Change in aBMD
GnRH agonist only
6 months
Diamond et al.45 18 78 FN− 6.5%; WT− 7.5%; Troch− 6.2%
Maillefert et al.21 12 70 LS− 3.0%; FN− 2.7%
Hamilton et al.44 26 71 LS− 1.7%; FN− 1.5%; Hip− 1.5%; 1/3Rad +9.1%
12 months
Maillefert et al.21 12 70 LS− 4.6%; FN− 3.9%
Berruti et al.15 35 75 LS− 2.3%; FN− 0.6%
Mittan et al.22 15 75 Hip− 3.3%; DRad− 5.3%; MRad− 2.7%; 1/3Rad− 1.6%; LS− 2.8%; FN− 2.3%
Bergstrom et al.14 10 73 FN− 3.2%
Smith et al.25 26 65 LS− 2.5%; Hip− 1.4%
Lee et al.20 65 66 Hip− 1.9%
Morote et al.23 31 70 LS− 4.8%; FN− 3.0%; WT− 5.6%; Troch− 3.6%; Hip− 3.8%
Hamilton et al.44 26 71 LS− 3.9%; FN− 3.0%; Hip− 2.6%; 1/3Rad +9.2%
18 months
Maillefert et al.21 12 70 LS− 6.6%; FN− 7.1%
Anti-androgen only
12 months
Smith et al.25 25 63 LS +2.5%; Hip +1.1%
CAB
9 months
Higano et al.19 17 69 LS− 4.5%; Hip− 2.5%
Galvão et al.17 69 74 Hip− 1.5%; LS− 3.9%; WB− 2.4%
Pharmacological (any modality)
12 months
Daniell et al.16 16 72 FN− 3.4%
Greenspan et al.18 80 69–71 Acute ADT: Hip− 2.5%; Troch− 2.4%; TRad− 2.6%; WB− 3.3%; LS− 4.0%; Chronic ADT: TRad− 2.0%
24 months
Daniell et al.16 16 72 FN− 6.5%
Preston et al.24 23 73 FN− 1.9%; Hip − 1.5%; Troch− 2.0%; LS− 0.2%; DRad +9.4%
Orchiectomy only
12 months
Daniell et al.16 10 77 FN− 2.4%
Bergstrom et al.14 12 79 FN− 4.5%
24 months
Daniell et al.16 10 77 FN− 10.0%
Abbreviations: 1/3Rad, one-third radius; aBMD, areal bone mineral density; ADT, androgen deprivation therapy; CAB, combined androgen blockade; DRad,
distal radius; FN, femoral neck; GnRH, gonadotropin-releasing hormone; Hip, total hip; LS, lumbar spine; MRad, mid radius; N, number; TRad, total radius; Troch,
trochanter; WB, whole body; WT, Ward’s triangle.
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Bone mineral density, structure and strength. Current guidelines
for managing bone health during ADT include several key
recommendations.37,40,61–63
First, aBMD and fracture risk assessment should be performed
prior to commencing ADT, after the ﬁrst 2 years of treatment, and
beyond this point pending individualised circumstances37,40,61
(Table 4). The use of DXA aBMD assessment within this population
group has previously been deemed a cost-effective strategy to
evaluate fracture risk.65 Despite these recommendations, it was
reported that only 10.2% of a cohort of 28 960 men were referred
to a DXA aBMD assessment prior to commencing ADT or within
the ﬁrst year of treatment.66
Second, dietary and supplemental calcium and vitamin D are
recommended, with recommended intakes varying from 1000–
1500 mg per day and 800–2000 IU per day, respectively.37,40,62,63
For men who are vitamin D deﬁcient (serum 25-hydroxyvitamin D
(25OHD) o50 nmol l− 1), it is recommended that they supplement
with 3000–5000 IU per day of vitamin D (pending level of
deﬁciency) for at least 6–12 weeks under the guidance of a
clinician.67 These recommendations are in line with a recent
review, which concluded that 500–1000 mg calcium and
200–500 IU vitamin D per day was not adequate to prevent bone
loss in men treated with ADT.68 In addition, Level 1 evidence from
healthy older adults indicates that daily calcium plus vitamin D
supplementation of 41000 mg and 4800 IU can reduce fracture
risk.67 Although it has been reported that an increased calcium
intake (or dairy consumption) may be associated with an
increased risk of PCa,69 calcium supplementation at doses of
o1500 mg per day were not found to be associated with PCa
progression.70 Similarly, vitamin D supplementation of 4000 IU
per day for 1 year was associated with no adverse effects or PCa
progression in men with PCa.71 Although further studies are
needed to evaluate the efﬁcacy of calcium and vitamin D on bone
health in men with PCa treated with ADT, based on the available
evidence it is advised that these men consider supplementation
with calcium and vitamin D under the guidance of their urologist
and/or general practitioner (Table 4).
Third, for patients who have experienced a minimal trauma
fracture have an initial aBMD hip or lumbar spine T-scores of o2.0
or have a 10-year absolute risk of major osteoporotic fracture of
420% as determined by FRAX (http://www.shef.ac.uk/FRAX),
antiresorptive therapy is recommended.37,40,61–63 The efﬁcacy of
antiresorptive therapy, such as bisphosphonates, has been
extensively reviewed and shown to prevent bone loss and fragility
fractures in men treated with ADT.72 However, in countries such as
Australia, the Pharmaceutical Beneﬁts Scheme only subsidises
Table 2. Non-randomised controlled trials examining the effects of
continual ADT in men with prostate cancer on lean tissue mass and fat
mass
Authors N Average
age (years)
Change in lean
tissue mass
(total body)
Change in fat
mass
GnRH agonist only
26 weeks
Boxer et al.31 30 72 − 2.1% +9.5%
Hamilton et al.44 26 71 − 3.2% +12.0%
48 weeks
Smith et al.27 32 66 − 2.7% +9.4%
52 weeks
Lee et al.20 65 66 − 2.0% +6.6%
Hamilton et al.44 26 71 − 3.6% +14.1%
CAB
12 weeks
Smith et al.29 25 68 − 1.4% NA
36 weeks
Galvão et al.17 72 74 − 2.4% +13.8%
52 weeks
Smith et al.28 26 65 − 3.6% +11.2%
Pharmacological (any modality)
24 weeks
Smith et al.30 22 67 − 2.7% NA
48 weeks
Smith26 79 71 − 3.8% NA
52 weeks
Greenspan et al.18 80 69–71 Acute ADT:
− 3.5%;
Chronic ADT:
NC
Acute ADT:
+10.4%
Chronic ADT:
NC
Abbreviations: ADT, androgen deprivation therapy; CAB, combined
androgen blockade; GnRH, gonadotropin-releasing hormone; N, number;
NA, not applicable; NC, no change.
Table 3. Clinical assessment and management guidelines for ADT-associated cardiometabolic and skeletal adverse effects
Cardiometabolic health
Metabolic risk assessment prior to ADT commencement: body mass index, waist circumference, blood pressure, fasting blood glucose, oral
glucose tolerance test (if fasting glucose between 5.5 and 6.9 mmol l− 1) and fasting lipid proﬁle.
Six-monthly to yearly metabolic assessment during the ﬁrst 24 months of ADT.
Lifestyle intervention and/or dietician to prevent weight gain and worsening of insulin resistance.
Smoking cessation.
Blood pressure o130/80 mm Hg.
Lipid targets according to NCEP ATP III treatment guidelines.
In men with diabetes, intensiﬁcation of management as necessary to main HbA1c target.
Skeletal health
At commencement of ADT: assessment for history of minimal trauma fractures and risk factors for osteoporosis, aBMD measurement by DXA and,
in men with osteopenia, postero-anterior as well as lateral thoracolumbar spine X-rays.
Yearly aBMD measurement during the ﬁrst 24 months of ADT.
Advice regarding regular physical exercise, smoking cessation and alcohol consumption of ⩽ 2 standard drinks per day at each visit.
Total daily calcium intake of 1200–1500 mg through diet, supplements, or both, unless there is a history of renal calculi.
Vitamin D supplementation as necessary to achieve a target serum 25-hydroxyvitamin D level ⩾ 75 nmol l− 1.
Commencement of treatment with a bisphosphonate in men with a minimal trauma fracture, an aBMD T-score of ⩽− 2.5, or if 10-year absolute
risk of a major osteoporotic fracture is 420%.
Abbreviations: aBMD, areal bone mineral density; ADT, androgen deprivation therapy; DXA, dual-energy X-ray absorptiometry; HbA1c, glycated haemoglobin;
NCEP ATP III, National Cholesterol Education Program Adult Treatment Panel III. Adapted from Cheung et al.64 on behalf of the Endocrine Society of Australia,
the Australian and New Zealand Bone and Mineral Society and the Urological Society of Australia and New Zealand.
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antiresorptive therapy for secondary prevention for those who
have suffered a minimal trauma fracture and primary prevention
for those aged over 70 years with T-scores ⩽− 2.5 or ⩽− 3.0,
pending therapy already prescribed. There may be a potential lack
of accessibility to these therapies in men treated with ADT in some
countries. Furthermore, there are concerns surrounding the overall
safety of antiresorptive therapy with adverse effects such as
ﬂu-like symptoms, hypercalcaemia and hepatic failure reported in
men treated with ADT.73 Finally, as antiresorptive therapy has no
effect on other key fracture risk factors, such as muscle strength,
muscle mass, balance and gait, all of which are associated with an
increased risk of falls and fracture, independent of BMD,
alternative or adjunct interventions should be made available to
patients currently undergoing ADT (Table 4).
Lifestyle measures such as exercise training, smoking cessation
and limited alcohol consumption (o2 standard drinks per day)
are an alternative to pharmacological intervention and are
commonly recommended in men treated with ADT.40,62 Sug-
gested exercise training modalities include weight-bearing aero-
bic training (AT; for example, walking), progressive resistance
training (PRT) and balance training.40,62 However, these guidelines
provide limited information on the precise exercise prescription
variables such as the training intensity, frequency and duration.
Despite initial concerns, regular exercise training has been shown
to have no effect on PSA or testosterone levels.74 Currently only
four studies have examined the role of exercise on skeletal
adaptations in men treated with ADT.75–78 Galvao et al.75 reported
that a 20-week PRT program, including two training sessions per
week utilising exercises that progressed from two sets at
12-repetition maximum (RM) to four sets at 6-RM, did not improve
femoral neck, trochanter or Ward’s triangle aBMD in 10 men
(mean age; 70 years) currently treated with ADT (mean duration;
3.1 years). Similarly, the ﬁndings from a 16-week PRT program in
28 men (mean age; 66 years) currently treated with ADT (mean
duration; 9 months) demonstrated no signiﬁcant differences in
femoral neck, trochanter, total hip and lumbar spine (L1-4) aBMD
when compared with men undergoing usual care (n= 30).78 In this
study, the training program included three sessions per week, with
each session including 9 exercises that progressed from two sets
of 10 repetitions at 40–50% 1-RM to 1–3 sets at 6–10-RM in a daily
undulating periodisation model.78 Consistent with these results,
Cormie et al.77 observed no signiﬁcant change in femoral neck or
lumbar spine (L2-4) aBMD, as well as tibia volumetric BMD
following a 12-week combined PRT and AT program in 32 men
(mean age; 70 years) initiating ADT when compared with usual
care (n= 31). The PRT component of the exercise program was
administered during two sessions per week and included eight
exercises progressing from 1–4 sets of 6–12RM.77 In all these
studies, the sample sizes were relatively modest and the lack of
any beneﬁcial skeletal effects was not unexpected given that
the typical bone remodelling cycle takes 6–8 months to
complete, and to demonstrate clinically relevant and observable
physiological changes, longer-term trials with appropriate sample
sizes are needed.
To date, only one trial of adequate duration has assessed the
role of exercise training on bone health in men treated with
ADT.76 Winters-Stone et al.76 reported that a 12-month targeted
PRT and weight-bearing impact loading program did not
Table 4. Recommendations for managing adverse effects of ADT in men with prostate cancer on bone health, lean tissue mass and fat mass
Densitometry
Prior to commencing ADT, men should undergo a DXA scan for the assessment of hip and spine bone mineral density and a total body scan for
the assessment of total and appendicular lean tissue mass and fat mass. These measures should be repeated yearly until the cessation of ADT.
Antiresorptive therapy
Clinicians should consider antiresorptive therapy if men: (1) experience a minimal trauma fracture, (2) have a hip and/or lumbar spine DXA-
assessed bone mineral density T-score of o2.0 or (3) have a 10-year absolute risk of major osteoporotic fracture of 420% as determined by
FRAX (http://www.shef.ac.uk/FRAX).
Exercise training
It is recommended that clinicians discuss and refer men to an individualised, multi-component exercise program incorporating the elements
below:
Progressive resistance training: at least twice per week, 8–10 exercises (targeting major muscle groups, speciﬁcally the muscle attached to or near
the hip and spine), 2–3 sets of 8–10 repetitions at moderate-to-high-intensity (70–85% of 1-RM or 5–8 ‘hard to very hard’ on the 10-point Borg
RPE scale).
Weight-bearing impact exercises (jumping, bounding, hopping, skipping and bench stepping): at least 4 days per week, 2–4 impact exercises
varying in magnitude and direction, progress to 50–100 jumps per session divided into 2–3 sets of 10–20 repetitions. *PRT is recommended ﬁrst
for those with low muscle strength and/or poor muscle function prior to commencing some impact activities.
Aerobic exercises: 5–7 days per week, 30 min of continuous, 55–75% of predicted heart rate maximum, modalities including cycling, walking,
rowing or sports such as tennis. Aerobic training can be divided into shorter bouts if required (three by 10 min sessions).
The concept of speciﬁcity and progressive overload should be applied to all exercises and when possible, programs should initially be performed
under the supervision of a tertiary-trained exercise professional (for example, an Accredited Exercise Physiologist in Australia).
Vitamin D
Prior to commencing ADT, men should have their serum 25(OH)D assessed. Men with 25(OH)D levels 450 nmol l− 1 (420 ng ml− 1) should
consider a daily supplement of 800 IU. Men with o50 nmol l− 1 should supplement with 3000–5000 IU per day for at least 6–12 weeks under the
guidance of a clinician.
Calcium
Include 3–4 serves of dairy food each day and if daily calcium intake is below the recommended dietary intake of 1000–1300 mg per day,
supplement with 600 mg per day.
Protein
Daily protein intake of at least 1.2 g kg−1 body weight per day.
Consume 25–30 g of high-quality protein with each meal and on exercise training days, within the ﬁrst few hours post exercise.
Tobacco and alcohol
Smoking cessation should be considered.
Alcohol consumption should be limited to o2 standard drinks per day.
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; ADT, androgen deprivation therapy; DXA, dual-energy X-ray absorptiometry; PRT, progressive resistance
training; RM, repetition maximum.
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signiﬁcantly improve femoral neck, total hip, greater trochanter or
lumbar spine (L1-4) aBMD in 29 men (mean age; 70 years)
currently treated with ADT (mean duration; 39 months) when
compared with an exercise placebo group consisting of stretching
(n= 22). It was suggested that due to concerns with treatment-
induced muscle weakness, frailty and incontinence, a cautious
approach was taken towards exercise prescription and this may
have not provided an adequate stimulus to elicit improvements in
aBMD.76 For example, the program only included one impact
exercise (two-footed jumps), performed three times per week,
which progressed from 10–50 repetitions and 0–10% body weight
(via weighted vests).76 Previous research in 180 healthy and
osteopenic older men (age range; 50–79 years) showed that a
combination of moderate-to-high-intensity PRT (60–85% 1-RM)
with weight-bearing impact exercises (90–180 impact loads)
performed three times per week that varied in the type,
magnitude and direction of loads was effective at improving
femoral neck (1.7%) and lumbar spine (L1-4; 2.1%) aBMD over
12 months compared with non-exercising controls.79 Similarly, a
meta-analysis of randomised controlled trials in older adults also
found that multi-component exercise programs incorporating
moderate-to-high-intensity PRT and weight-bearing impact exer-
cises were most effective for maintaining (or improving) hip and
spine aBMD.80 Although further studies are warranted to evaluate
the safety and efﬁcacy of targeted, multi-component exercise
program on bone health in this susceptible population group,
based on the available evidence in healthy and osteopenic older
men, it is advised that men treated with ADT be prescribed a
similar exercise program under the supervision of an appropriately
qualiﬁed exercise physiologist or trainer (Table 4).
Lean tissue mass. The guidelines for managing metabolic health
during ADT brieﬂy discuss the link between lean tissue mass and
insulin resistance, yet do not recommend any interventions
speciﬁcally intended to preserve or improve muscle
health.37,40,61,63 Regular exercise training and/or physical activity
are recommended, but greater emphasis is placed on weight
management as an outcome, rather than lean tissue
mass.37,40,61,63 In healthy older men, there is consistent and
compelling evidence demonstrating that PRT is safe and effective
for improving muscle mass and strength, with the greatest
beneﬁts typically observed with high-intensity training.81 How-
ever, in men with PCa treated with ADT, a recent systematic
review74 concluded that there was inadequate evidence to
produce speciﬁc exercise prescription guidelines for this popula-
tion group, and therefore suggested that these men adopt
general guidelines for cancer patients.82–85 For example, Exercise
and Sport Science Australia83 recommend 1–3 PRT sessions per
week that include 6–10 exercises targeting different muscle
groups, completed at an intensity of 50–80% 1-RM or 6–12-RM in
sets of 1–4. A growing body of evidence examining the role of
exercise training in men treated with ADT has shown that
interventions including at least two PRT sessions per week for
12 weeks or greater can maintain77,78,86 or improve87 (0.5–0.7 kg)
total body and/or appendicular lean tissue mass. In contrast, no
improvement in lean tissue mass was demonstrated following a
24-week AT program, including three sessions per week progres-
sing from 15–45 min at an intensity of 50–75% VO2peak, in 25
men (mean age; 66 years) treated with ADT (mean duration;
106 days).86 Therefore, it is advised that all men treated with ADT
be prescribed a moderate-to-high-intensity PRT program, with a
speciﬁc focus on muscles attached to or near the hip, spine and
forearm, as these are the most common fracture sites (Table 4).
Emerging evidence in older adults has also provided a rationale
for the potential use of protein supplementation alongside PRT in
clinical populations susceptible to muscle loss, such as those
treated with ADT.88 Although yet to be examined within this
population group, a recent meta-analysis of randomised
controlled trials conducted in healthy older adults concluded that
protein supplementation combined with PRT may elicit further
gains in muscle mass than PRT alone.88 However, the responses
appeared to vary according to the type, amount, spread and/or
change in protein intake, timing, pattern or distribution of intake
and the potential inﬂuence of co-ingestion with other nutrients.89
There is a growing body of evidence to suggest that high-quality,
rapidly digested, leucine-rich protein sources (for example, whey
protein), when compared with other types of protein supplemen-
tation (for example, casein and soy), can produce additive or
synergistic beneﬁts on post-exercise skeletal muscle protein
synthesis and promote increases in muscle mass in older
adults.90 Similarly, emerging evidence suggests that 20–40 g of
high-quality protein may be required to elicit maximal gains in
muscle mass in older adults.91 Moreover, the timing of protein
ingestion in relation to the exercise session is also important with
early (within 1–4 h) post-PRT consumption of protein reported to
be most effective for optimising muscle protein synthesis.91,92 Due
to the lack of randomised controlled trials examining the role of
protein supplementation in men treated with ADT, the potential
disease-speciﬁc risks are unknown, however increased protein
intake is commonly shown to be well tolerated and accompanied
by no serious adverse events in older population groups.93,94
Therefore, further evaluation is still required in men treated with
ADT to elucidate both the risks and beneﬁts of protein
supplementation when used in combination with exercise training
as a strategy to optimise muscle health (Table 4).
Fat mass. Most guidelines for managing adverse effects of ADT
have placed greater emphasis on weight management, and do
not speciﬁcally focus on monitoring and preventing the accumu-
lation of fat mass via robust measures such as DXA.37,40 Although
not speciﬁcally stated within the current guidelines,37,40 exercise
training is one potential intervention to address the accumulation
of fat mass during ADT. However, evidence regarding the efﬁcacy
of exercise training in reducing fat mass during ADT is currently
mixed.77,78,87,95,96 In a sample of 32 men (mean age; 70 years)
commencing ADT, fat mass was shown to decrease by 0.6 kg
following a 12-week-combined PRT and AT program when
compared with usual care (n= 31).77 Exercise training was
conducted twice weekly and involved 20–30 min AT at 70–85%
of estimated heart rate maximum and PRT prescribed at 6–12-RM
in sets of 1–4.77 Similarly, a 24-week PRT program performed three
times per week (1–2 sets of 8–12 repetitions at 60–70% 1-RM)
decreased the accumulation of body fat percentage when
compared with usual care (+0.4% vs +3.2%), whereas a concurrent
AT program also performed three times per week (progressing
from 15–45 min at 50–75% of maximal heart rate) of the trial
showed no change to fat mass when compared with usual care.86
No change in fat mass was also observed following interventions
including PRT performed two or more times per week for 12–52
weeks.78,87,96 Despite these negative ﬁndings, the lack of change
in fat mass may be viewed as beneﬁcial due to the expected
accumulation of fat mass during ADT. Although it is clear that
further studies are needed to evaluate the effect of various types
and dose of exercise training on total body and regional fat in
men with PCa treated with ADT, it is recommended that AT be
included as part of a multi-component exercise program for men
with PCa treated with ADT (Table 4).
CONCLUSION
Despite ADT improving overall survival in appropriately selected
patients, it is accompanied with a range of adverse effects,
including negative alterations to BMD, structure and strength, lean
tissue mass and fat mass, which may contribute to the increased
risk of osteoporosis, falls, fractures and cardiometabolic-related
events observed in this population group. Although various
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guidelines exist for men with PCa treated with ADT, there is a need
to implement and evaluate the growing body of evidence
supporting the use of lifestyle interventions to ameliorate and
manage the adverse effects of ADT. Clinicians should consider
referring suitable men to practitioners within the allied health
profession (for example, exercise physiologists and dieticians) to
ensure these men receive the greatest quality of evidence-based
care. Our proposed recommendations are outlined in Table 4.
Future trials are required to assess both the risk and beneﬁts of
adhering to these guidelines and only then may these be fully
incorporated into standard practice for men treated with ADT.
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